Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Precipitation Of Cardiac Arrest By Verapamil In Patients With Wolff-parkinson-white Syndrome.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Precipitation Of Cardiac Arrest By Verapamil In Patients With Wolff-parkinson-white Syndrome.

    • Related Experiment Videos

    Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome.

    B McGovern, H Garan, J N Ruskin

      Annals of Internal Medicine
      |June 1, 1986

      View abstract on PubMed

      Summary
      This summary is machine-generated.

      Verapamil administration can trigger ventricular fibrillation in patients with Wolff-Parkinson-White syndrome, particularly those with atrial fibrillation. This drug should be avoided in these high-risk tachycardia patients.

      Related Experiment Videos

      Area of Science:

      • Cardiology
      • Electrophysiology

      Background:

      • Verapamil is used for rapid tachycardias.
      • Wolff-Parkinson-White syndrome involves accessory pathways.
      • Atrial fibrillation with preexcitation poses risks.

      Purpose of the Study:

      • To report adverse events associated with verapamil in patients with Wolff-Parkinson-White syndrome.
      • To highlight the danger of verapamil in specific tachyarrhythmias.

      Main Methods:

      • Case series of five patients presenting with tachyarrhythmias.
      • Administration of intravenous verapamil (5-10 mg).
      • Electrocardiogram and intracardiac electrophysiologic studies.

      Main Results:

      • Five patients developed ventricular fibrillation or required cardioversion after verapamil.
      • Episodes occurred during treatment for tachycardias, often atrial fibrillation with preexcitation.
      • Electrophysiologic studies confirmed accessory atrioventricular pathways with rapid conduction.

      Conclusions:

      • Verapamil can precipitate life-threatening ventricular fibrillation in Wolff-Parkinson-White syndrome.
      • Avoid verapamil in patients with atrial fibrillation and preexcited ventricular complexes.
      • This adverse response underscores the importance of careful drug selection in managing tachycardias.